Surrogate endpoints (e.g., HbA1c for glycemic control, blood pressure for cardiovascular risk) shorten trial duration but require evidence that change in the surrogate predicts clinically meaningful benefit. FDA lists accepted surrogates for drugs, and device teams must justify surrogates through literature, mechanistic evidence and links to clinical outcomes. Validated surrogates can support approval, while less established ones may support approval only with post-approval studies confirming clinical benefit. Payers and HTA bodies often scrutinize surrogates more strictly than regulators.

Why it matters

Increasingly important for IVD and digital biomarker submissions; FDA maintains a Surrogate Endpoint Table for drug approvals that informs device thinking.

Common pitfalls

•Over-reliance on a surrogate endpoint without sufficient clinical validation can lead to regulatory rejection.
•Selecting a surrogate endpoint that does not accurately reflect the patient population or disease progression is a common mistake.
•Failing to establish a clear and evidence-backed correlation between the surrogate endpoint and the true clinical outcome is a critical pitfall.
•Underestimating the data requirements for validating a surrogate endpoint can delay trial progress.

Sources

FDA Surrogate Endpoints · FDA
ISO 14155 Standard Page · ISO
FDA - Clinical Trials and Human Subject Protection · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.